The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Neuro-Cardiac Genetic Basis Of Sudden Unexpected Death In Epilepsy
Funder
National Health and Medical Research Council
Funding Amount
$575,288.00
Summary
Sudden unexpected death in epilepsy (SUDEP) is the most common epilepsy-related cause of death and accounts for up to 18% of all deaths. SUDEP is characterised by a sudden and unexpected death, where the post-mortem is normal. The underlying cause of SUDEP remains unknown. This study seeks to investigate the genetic causes of SUDEP. Identification of the causes of SUDEP has important implications for our understanding of disease mechanisms, and in translating these discoveries into both diagnost ....Sudden unexpected death in epilepsy (SUDEP) is the most common epilepsy-related cause of death and accounts for up to 18% of all deaths. SUDEP is characterised by a sudden and unexpected death, where the post-mortem is normal. The underlying cause of SUDEP remains unknown. This study seeks to investigate the genetic causes of SUDEP. Identification of the causes of SUDEP has important implications for our understanding of disease mechanisms, and in translating these discoveries into both diagnostic and prevention strategies in at-risk families.Read moreRead less
Sudden cardiac death (SCD) is a tragic consequence of a number of heart diseases. The death is often unexpected and has major implications for the family and community. This 3-year study seeks to evaluate clinical, genetic, and long-term outcomes in Australian families where SCD has occurred in a young relative (aged 1-35 years). This study will improve clinical and genetic evaluation of families, resulting in targeted management strategies, with the ultimate goal to prevent SCD.
New Gene Discovery In Familial Hypertrophic Cardiomyopathy
Funder
National Health and Medical Research Council
Funding Amount
$418,493.00
Summary
Familial hypertrophic cardiomyopathy is a genetic heart disorder which affects 1 in 500 of the population, and can lead to heart failure and sudden death. Identification of the genetic causes of hypertrophic cardiomyopathy has important implications for our understanding of this disease, and in translating these genetic discoveries into better diagnostic and prevention strategies in at-risk families. This research proposal seeks to perform a comprehensive clinical and genetic investigation of pe ....Familial hypertrophic cardiomyopathy is a genetic heart disorder which affects 1 in 500 of the population, and can lead to heart failure and sudden death. Identification of the genetic causes of hypertrophic cardiomyopathy has important implications for our understanding of this disease, and in translating these genetic discoveries into better diagnostic and prevention strategies in at-risk families. This research proposal seeks to perform a comprehensive clinical and genetic investigation of people with familial hypertrophic cardiomyopathy.Read moreRead less
Preclinical Assessment Of Gene Therapy For Ventricular Arrhythmia
Funder
National Health and Medical Research Council
Funding Amount
$801,079.00
Summary
Up to 10% of patients are at risk of sudden death following myocardial infarction. Current treatment and preventative initiatives have their limits and are not without risk. In this proposal we will continue to develop an exciting new treatment approach using gene therapy technology. We will attempt to overcome some of the barriers for human application of this technology and pave the way for early phase clinical trials.
The Structural Basis For Promiscuity Of Drug Binding To HERG K+ Channels
Funder
National Health and Medical Research Council
Funding Amount
$713,035.00
Summary
Special proteins called ion channels control the electrical activity of the heart. Drugs that block ion channels can have the unwanted side-effect of altering the rhythm of the heart beat and causing sudden cardiac death. Extensive efforts are made to screen for this problem during drug development but it is still an inexact science. Here we will use high resolution imaging technologies to get a better understanding of how drugs bind to ion channel proteins.
Cardiac Resynchronisation Therapy And AV Node Ablation For Atrial Fibrillation In Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$3,274,979.00
Summary
Heart failure (HF) and Atrial Fibrillation (AF) are both significant health issues that often coexist. Cardiac resynchronisation therapy (CRT) is a proven therapy for HF with ventricular dyssynchrony (uncoordinated contraction of the left ventricle). While CRT reduces symptoms and improves survival in normal rhythm, there are mixed reports in patients with AF. This prospective randomised multicentre study, will assess the role of AV node ablation to improve outcomes in CRT in AF.
Cell Therapy For Prevention Of Perinatal Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$539,337.00
Summary
Exposure of babies to infection or inflammation before birth is common and is associated with preterm delivery and illness in newborns. The biggest problem for these babies is lung disease due to inflammation of the lungs before birth and/or in response to lung injury after birth. There is no treatment for the underlying inflammation and no way to prevent or treat the lung disease that it causes. This project will investigate a new stem-cell based treatment for lung inflammation that may prevent ....Exposure of babies to infection or inflammation before birth is common and is associated with preterm delivery and illness in newborns. The biggest problem for these babies is lung disease due to inflammation of the lungs before birth and/or in response to lung injury after birth. There is no treatment for the underlying inflammation and no way to prevent or treat the lung disease that it causes. This project will investigate a new stem-cell based treatment for lung inflammation that may prevent life-threatening lung disease in preterm babies.Read moreRead less
Amniotic Exosomes - Nanomedicine For Bronchopulmonary Dysplasia
Funder
National Health and Medical Research Council
Funding Amount
$647,058.00
Summary
Extremely premature babies are at serious risk of developing a life threatening chronic lung disease known as bronchopulmonary dysplasia. This is expensive to treat and even babies who survive often end up with lifelong complications. Our team believes that nanoparticles released by placental stem cells have the ability to reverse the disease and that this can be administered without complex medical tools so that parents can administer it themselves after discharge.
Serial NT-proBNP Monitoring For Predicting Major Cardiovascular Events In The Dialysis Population
Funder
National Health and Medical Research Council
Funding Amount
$288,548.00
Summary
Dialysis patients have a 50-100 fold increased risk of dying from heart disease caused by abnormal heart muscle structure and function. Current tests are unable to accurately identify patients at the highest risk. A test that accurately detects the early stages of heart injury is urgently needed. The aim of our research is to develop a monitoring guide using regular testing of a heart hormone (NT-proBNP) to identify high-risk dialysis patients early allowing treatment before a serious medical co ....Dialysis patients have a 50-100 fold increased risk of dying from heart disease caused by abnormal heart muscle structure and function. Current tests are unable to accurately identify patients at the highest risk. A test that accurately detects the early stages of heart injury is urgently needed. The aim of our research is to develop a monitoring guide using regular testing of a heart hormone (NT-proBNP) to identify high-risk dialysis patients early allowing treatment before a serious medical complication occurs.Read moreRead less
Human Amnion Epithelial Cell Therapy For Bronchopulmonary Dyspliasa
Funder
National Health and Medical Research Council
Funding Amount
$1,048,035.00
Summary
Preterm infants, especially those born very early, commonly develop a type of chronic lung disease called bronchopulmonary displasia (BPD). There is currently no cure or means of preventing BPD. Cells from the amniotic membrane that surrounds the developing baby before birth show promise as a treatment, or perhaps even a way of preventing, BPD. This project will use a preterm lamb model of BPD to assess the ability of amnion cells to treat or prevent the disease.